This includes all‐trans‐retinoic acid (ATRA) targeted therapy for RAR rearranged AML, FLT3 inhibitors for FLT3 mutated subtypes, IDH1/2 inhibitors for IDH mutated groups and hypomethylating agents. Here, IDH1 is linked to acute myeloid leukemia.